Table S4. NS3 T cell epitopes found in the literature. A) T helper epitopes



Similar documents
Identification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans

A white paper for consideration by the NIAID Microbial Sequencing Program

Hepatitis C Vaccines: Are we making progress?

Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

International Journal of Integrative Biology A journal for biology beyond borders ISSN

Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection

6. JR Larrubia, MU Lokhande, S García-Garzón, J Miquel, A González-Praetorius, E Sanzde-Villalobos.

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

Hepatitis C Glossary of Terms

TRANSGENE SA, FRANCE 2. INSTITUT PASTEUR, FRANCE On behalf. AFEF 2013, Lille 02 nd October 2013

New HLA class I epitopes defined by murine monoclonal antibodies

TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS

Co-infected health-care workers

The hepatitis B virus (HBV)

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

Analysis of the adaptive immune response to West Nile virus

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

There are about 170 million carriers of hepatitis C virus

Modelling and analysis of T-cell epitope screening data.

Several human pathogens have the ability to suppress immune

Treatment of Acute Hepatitis C

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Assays to evaluate cell-mediated immunity. Guus Rimmelzwaan Department of Virology Erasmus Medical Center Rotterdam The Netherlands

HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations

TOWARDS AN HIV VACCINE

UPDATE ON NEW HEPATITIS C MEDICINES

The challenge of developing a vaccine against hepatitis C virus

Human Leukocyte Antigens - HLA

Case Finding for Hepatitis B and Hepatitis C

PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands

PEPVAC: A web server for multi-epitope vaccine development based on the prediction of supertypic

Detection of T-cell T and their application to vaccine design

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

The Costimulatory Molecule CD27 Maintains Clonally

T cell Epitope Prediction

Medical publications on HBV and HCV Coinfection

Positive impact of HCV treatment initiation on health outcomes in injecting drug users

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

III III a IIOI OlD III OlD IIO III DID III 100 III0 II uii IIi

Acute viral hepatitis B (AVH-B) is successfully. A Randomized Controlled Trial of Lamivudine to Treat Acute Hepatitis B. Patients and Methods

Early HIV- specific CD8 + T cell responses in treated and untreated hyper acute HIV infec=on in the FRESH cohort

Hapten - a small molecule that is antigenic but not (by itself) immunogenic.

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Hepatitis C: Epidemiology, Transmission, and Screening. Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco

THE INFLUENCE OF TISSUE (IN)COMPATIBILITY IN UMBILICAL CORD BLOOD TRANSPLANTATION

Title: Mapping T cell epitopes in PCV2 capsid protein - NPB # Date Submitted:

Mid-Clinical Stage Antiviral Drug Development Company

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

BioMmune Technologies Inc. Corporate Presentation 2015

Hing wars. During World War II, there was a series of hepatitis outbreaks

T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus

The immunogenicity of the Hepatitis C virus (HCV) non- structural protein 3 (NS3) was investigated using different

New developments in antigen-specific immunotherapies Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer

Final Review. Aptamers. Making Aptamers: SELEX 6/3/2011. sirna and mirna. Central Dogma. RNAi: A translation regulation mechanism.

Chapter 43: The Immune System

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

AAB 2013 Annual Meeting & Educational Conference

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Cancer Vaccines and the Importance of Overcoming Immunological T-Cell Response

CHARACTERISTICS OF CHRONIC HEPATITIS C AMONG INTRAVENOUS DRUG USERS: A COMPARATIVE ANALYSIS

Interleukin-10 gene promoter polymorphism and risk of liver cirrhosis

Identification of CD8 + T Cell Epitopes in the West Nile Virus Polyprotein by Reverse-Immunology Using NetCTL

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid

Immune Epitope Database NEWSLETTER Volume 7, Issue 1 March 2010

Vaccine Development for Hepatitis C: Lessons from the Past Turn into Promise for the Future

Cytoreductive Therapy for Autologous Cell Therapy in HIV

In this study, the DCV+ASV regimen had low rates of discontinuation (5%) due to adverse events, and low rates of serious adverse events (5.

Downloaded from:

G V Papatheodoridis, S G R G Barton, D Andrew, G Clewley, S Davies, A P Dhillon, G Dusheiko, B Davidson, K Rolles, A K Burroughs

CD8+ T Cell Response to Interruptible Chronic HCV Infection

Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics

HBV DNA < monitoring interferon Rx

Prediction of T cell epitopes for the utility of vaccine development from structural proteins of dengue virus variants using in silico methods

Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes

João Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil

HCV: Diagnostic Testing and Staging. HCV: Diagnostic Tests

DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME

The immunogenic vaccine against HCV and HBV

The Natural History of Chronic Hepatitis B Virus Infection

The natural history of chronic HBV infection

Global Under Diagnosis of Viral Hepatitis

Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency

The autophagy machinery is required to initiate hepatitis C virus infection. Marlène Dreux

Optimising therapy in chronic hepatitis B: Switch or add treatment

Fat and Viral Liver Disease

HLA Class I-Restricted Cytotoxic T-Cell Epitopes of the Respiratory Syncytial Virus Fusion Protein

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection

Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

HEPATITIS COINFECTIONS

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

Liver Disease and Therapy of Hepatitis B Virus Infections

Clinical Application of HBs quantification

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

DNA Vaccine for Chronic Hepatitis C

3/25/2014. April 3, Dennison MM, et al. Ann Intern Med. 2014;160:

Transcription:

Table S4. NS3 T cell epitopes found in the literature A) T helper epitopes Epitope Protein Position Genotype MHC II Association Reference TRTIASPKGPVIQMY NS3 1087-1101 1A class II (4) DLVGWPAPQGSRSLT NS3 1107-1121 1A class II (4) CPAGHAVGIFRAAVCTRGVA NS3 1171-1190 1A QGYKVLVLNPSVAAT NS3 1247-1261 1A DRB1*0101, DRB1*0401, DRB1*1501,DRB1*0404 (23) DRB1*0101, DRB1*0401, DRB1*1001,DRB1*1104 (23) GGRHLIFCHSKKKCD NS3 1387-1401 1B DR13,DR15 (9) LIFCHSKKKCDELAA NS3 1391-1405 1A DRB1*15 (4) HSKKKCDEL NS3 1395-1403 1A/1B DRB1*15 (4) TQTVDFSLDPTFTIE NS3 1459-1473 1B DR13,DR15 (9) EQYVDFSLDPTFSIE NS3 1465-1479 3A class II (16) MFDSSVLCECYDAGC NS3 1511-1525 1A/1B DR7, DR13 (9) TTVRLRAYMNTPGLPV NS3 1531-1550 1B DRB1*0701 (23) FPYLVAYQATVCARA NS3 1583-1597 1B DR13,DR15 (9) TAYQATVCARAQAPP NS3 1593-1607 3A class II (16) YLVAYQATVCARAQAP NS3 1585-1600 1B DRB1*1001 (23)

B) CTL epitopes Epitope Protein Position Genotype MHC I Association Reference AYSQQTRGL NS3 1031-1039 1B A24 (3) VEGEVQIVSTAAQTF NS3 1055-1069 1A class I (4) CINGVWCTV NS3 1073-1081 1A A2 (5) QTFLATCINGVCWTV NS3 1067-1081 1A class I (4) ATCINGVCWTVYHGAGTRTI NS3 1071-1090 1A class I (6) TRTIASPKGPVIQMY NS3 1087-1101 1A class I (4) AGTRTIASPKGPVIQM NS3 1085-1100 1A class I (7) MYTNVDQDL NS3 1100-1108 1A A24 (8) RRRGDSRGSLLSPRP NS3 1143-1157 1B class I (9) LLCPAGHAV NS3 1169-1177 1A A2 (10) CPAGHAVGIFRAAVCTRGVA NS3 1171-1190 1A A2 (6) HAVGLFRAA NS3 1175-1183 1A A68 (6) AYAAQGYKVL NS3 1243-1252 1B Cw*0303, Cw*0304 (11) TLGFGAYMSK NS3 1261-1270 1A A11 (12) GAYMSKAHGV NS3 1265-1274 1A/1B A11 (13) LGFGAYMSK NS3 1262-1270 1A A3 (10) TITTGAPVTYSTYGK NS3 1284-1298 1B A2 (14) TGAPVTYSTY NS3 1287-1296 1B A2 (14) TGSPITYSTY NS3 1287-1296 1A A2 (10) TYSTYGKFL NS3 1292-1300 1A/1B A*2402 (15) CHAQDATTVL NS3 1318-1327 3A B38 (16) HPNIEEVAL NS3 1359-1367 1A/1B B*3501 (7) GEIPFYGKAI NS3 1376-1385 3A B44 (17) GEIPFYGKAI NS3 1371-1380 1A C*1402 (7) FYGKAIPIEAI NS3 1375-1385 1B A*2402 (11) HSKKKCDEL NS3 1395-1403 1A/1B B8 (4) HSKRKCDEL NS3 1395-1403 1A/1B class I (7) HSKKKCDELT NS3 1395-1404 1A B8 (18) ELAAKLVAL NS3 1402-1410 1A B8 (19) ELAAKLVGL NS3 1402-1410 1A B8 (20) LAAKLVALGINAVAY NS3 1403-1417 1A A2 (6) ATDALMTCY NS3 1436-1444 1A A1 (21) DVVVVATDALMTGYT NS3 1431-1445 1A class I (4) GDVVVVSTDALMTGY NS3 1430-1444 1A class I (7) ALMTGYTGDFDSVI NS3 1439-1452 1A class I (7) STDALMTGFTGDFDS NS3 1436-1450 1A class I (22) GFTGDFDSV NS3 1443-1451 1A/1B A*0206 (11) CLIRLKPTLHGPTPLLYR NS3 1610-1627 1A/1B class I (6) LIRLKPTL NS3 1611-1618 1A/1B B8 (6) TLTHPVTK NS3 1636-1643 1A A11 (12) EVTLTHPITKYIMTCMSA NS3 1634-1651 1A/1B B8 (18) TLTHPITK NS3 1636-1643 1A/1B A11 (18)

Supplementary references 1. Yamada, N., K. Tanihara, M. Mizokami, K. Ohba, A. Takada, M. Tsutsumi, and T. Date. 1994. Full-length sequence of the genome of hepatitis C virus type 3a: comparative study with different genotypes. J Gen Virol 75 ( Pt 11):3279-3284. 2. Kolykhalov, A.A., E.V. Agapov, K.J. Blight, K. Mihalik, S.M. Feinstone, and C.M. Rice. 1997. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277:570-574. 3. Kurokohchi, K., K. Arima, and M. Nishioka. 2001. A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection. J Hepatol 34:930-935. 4. Wertheimer, A.M., C. Miner, D.M. Lewinsohn, A.W. Sasaki, E. Kaufman, and H.R. Rosen. 2003. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37:577-589. 5. Cerny, A., P. Fowler, M.A. Brothers, M. Houghton, H.J. Schlicht, and F.V. Chisari. 1995. Induction in vitro of a primary human antiviral cytotoxic T cell response. Eur J Immunol 25:627-630. 6. Lauer, G.M., E. Barnes, M. Lucas, J. Timm, K. Ouchi, A.Y. Kim, C.L. Day, G.K. Robbins, D.R. Casson, M. Reiser, G. Dusheiko, T.M. Allen, R.T. Chung, B.D. Walker, and P. Klenerman. 2004. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127:924-936. 7. Cox, A.L., T. Mosbruger, Q. Mao, Z. Liu, X.H. Wang, H.C. Yang, J. Sidney, A. Sette, D. Pardoll, D.L. Thomas, and S.C. Ray. 2005. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201:1741-1752.

8. Ito, A., T. Kanto, N. Kuzushita, T. Tatsumi, Y. Sugimoto, T. Miyagi, T. Takehara, K. Katayama, K. Mochizuki, N. Hiramatsu, A. Kasahara, I. Yoshiya, Y. Sasaki, M. Hori, and N. Hayashi. 2001. Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells. J Gastroenterol Hepatol 16:309-316. 9. Dutoit, V., D. Ciuffreda, D. Comte, J.J. Gonvers, and G. Pantaleo. 2005. Differences in HCVspecific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur J Immunol 35:3493-3504. 10. Rosen, H.R., G. Marousek, and S. Chou. 2002. A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation. Transplantation 74:209-216. 11. Hakamada, T., K. Funatsuki, H. Morita, T. Ugajin, I. Nakamura, H. Ishiko, Y. Matsuzaki, N. Tanaka, and M. Imawari. 2004. Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-a*2402- binding motifs. J Gen Virol 85:1521-1531. 12. Wong, D.K., D.D. Dudley, N.H. Afdhal, J. Dienstag, C.M. Rice, L. Wang, M. Houghton, B.D. Walker, and M.J. Koziel. 1998. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 160:1479-1488. 13. Cucchiarini, M., A.R. Kammer, B. Grabscheid, H.M. Diepolder, T.J. Gerlach, N. Gruner, T. Santantonio, J. Reichen, G.R. Pape, and A. Cerny. 2000. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 203:111-123. 14. Kurokohchi, K., T. Akatsuka, C.D. Pendleton, A. Takamizawa, M. Nishioka, M. Battegay, S.M. Feinstone, and J.A. Berzofsky. 1996. Use of recombinant protein to identify a motifnegative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 70:232-240.

15. Nakamoto, Y., S. Kaneko, H. Takizawa, Y. Kikumoto, M. Takano, Y. Himeda, and K. Kobayashi. 2003. Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers. J Med Virol 70:51-61. 16. Guglietta, S., A.R. Garbuglia, V. Pacciani, C. Scotta, M.P. Perrone, L. Laurenti, E. Spada, A. Mele, M.R. Capobianchi, G. Taliani, A. Folgori, A. Vitelli, L. Ruggeri, A. Nicosia, E. Piccolella, and P. Del Porto. 2005. Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection. Eur J Immunol 35:2627-2637. 17. Sidney, J., S. Southwood, V. Pasquetto, and A. Sette. 2003. Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype. J Immunol 171:5964-5974. 18. Timm, J., G.M. Lauer, D.G. Kavanagh, I. Sheridan, A.Y. Kim, M. Lucas, T. Pillay, K. Ouchi, L.L. Reyor, J. Schulze zur Wiesch, R.T. Gandhi, R.T. Chung, N. Bhardwaj, P. Klenerman, B.D. Walker, and T.M. Allen. 2004. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200:1593-1604. 19. Giuggio, V.M., H.L. Bonkovsky, J. Smith, and A.L. Rothman. 1998. Inefficient recognition of autologous viral sequences by intrahepatic hepatitis C virus-specific cytotoxic T lymphocytes in chronically infected subjects. Virology 251:132-140. 20. Ward, S., G. Lauer, R. Isba, B. Walker, and P. Klenerman. 2002. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 128:195-203. 21. Lauer, G.M., K. Ouchi, R.T. Chung, T.N. Nguyen, C.L. Day, D.R. Purkis, M. Reiser, A.Y. Kim, M. Lucas, P. Klenerman, and B.D. Walker. 2002. Comprehensive analysis of CD8(+)-Tcell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76:6104-6113. 22. Kennedy, P.T., S. Urbani, R.A. Moses, B. Amadei, P. Fisicaro, J. Lloyd, M.K. Maini, G. Dusheiko, C. Ferrari, and A. Bertoletti. 2006. The influence of T cell cross-reactivity on HCVpeptide specific human T cell response. Hepatology 43:602-611.

23. Schulze zur Wiesch, J., G.M. Lauer, C.L. Day, A.Y. Kim, K. Ouchi, J.E. Duncan, A.G. Wurcel, J. Timm, A.M. Jones, B. Mothe, T.M. Allen, B. McGovern, L. Lewis-Ximenez, J. Sidney, A. Sette, R.T. Chung, and B.D. Walker. 2005. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 175:3603-3613.